Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with a significant chance of healing in lymphoid hematological refractory or multiple relapses after chemotherapy. However, all patients with an indication of allo-HSC can not benefit because of two limitations: the toxicity of the treatment and graft shortage available. For patients refractory or in relapses with an indication of allo-HSC, used the combinaison of an SET followed by the reduced-intensity allo-HSC (RIC) has shown some interesting results. A post-transplant immune modulation with prophylactic injections of donor lymphocytes (PDLI) showed its effectiveness to decrease the risk of relapse while having a lower toxicity than chemotherapy
Timeline
- Start
- 2017-06-30
- Primary completion
- 2023-09-11
- Completion
- 2023-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |
| Subject | Cyclophosphamide | Other / unclassified | 400 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |
| Subject | Thiotepa | Other / unclassified | 5 mg/kg | — |
| Subject | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | — |
| Background | Cyclosporine | Peptide | 3 mg/kg | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 30 mg/kg | — |